Literature DB >> 19515092

Discordance in HIV-1 viral loads and antiretroviral drug concentrations comparing semen and blood plasma.

G Lorello1, C la Porte, R Pilon, G Zhang, T Karnauchow, P MacPherson.   

Abstract

OBJECTIVES: For individuals not on antiretroviral therapy, the risk of heterosexual transmission of HIV appears negligible when blood plasma (BP) viral loads are <1500 HIV-1 RNA copies/mL. It is not clear whether this observation can be extrapolated to individuals on highly active antiretroviral therapy (HAART). Because of differential tissue penetration, antiretroviral drug concentrations may be sufficient to maintain an undetectable viral load in the BP yet not achieve adequate levels to suppress HIV in the genital tract. Therefore, we wanted to correlate HIV viral loads and drug concentrations in semen plasma (SP) and BP.
METHODS: Thirty-three men were included. All were on combination antiretroviral therapy with an undetectable BP viral load for at least 1 year. Blood and semen samples were collected within 2 h of each other and tested for HIV RNA by the NucliSens QT (bioMerieux, St Laurent, QC, Canada) method; drug concentrations were determined by liquid chromatography tandem mass spectrometry.
RESULTS: Two of the 33 patients (6.1%) with BP viral loads below detection had time-matched HIV viral loads in SP > or =700 copies/mL. Both patients were on efavirenz, the SP concentrations of which were < or =10% of the levels in BP and well below the minimal therapeutic drug monitoring target concentration required to suppress HIV.
CONCLUSIONS: Because, at least in part, of poor drug penetration into the genital tract, an undetectable HIV viral load in the BP does not guarantee an undetectable viral load in semen. In view of this, caution should be taken in concluding that patients on HAART with suppressed viraemia are sexually non-infectious.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19515092     DOI: 10.1111/j.1468-1293.2009.00725.x

Source DB:  PubMed          Journal:  HIV Med        ISSN: 1464-2662            Impact factor:   3.180


  23 in total

Review 1.  HIV treatment as prevention in men who have sex with men: examining the evidence.

Authors:  Patrick O'Byrne; Paul MacPherson
Journal:  CMAJ       Date:  2015-12-22       Impact factor: 8.262

2.  Detection of Simian Immunodeficiency Virus in Semen, Urethra, and Male Reproductive Organs during Efficient Highly Active Antiretroviral Therapy.

Authors:  G Matusali; N Dereuddre-Bosquet; A Le Tortorec; M Moreau; A-P Satie; D Mahé; P Roumaud; O Bourry; N Sylla; S Bernard-Stoecklin; A Pruvost; R Le Grand; N Dejucq-Rainsford
Journal:  J Virol       Date:  2015-04-01       Impact factor: 5.103

3.  Role of donor genital tract HIV-1 diversity in the transmission bottleneck.

Authors:  Debrah I Boeras; Peter T Hraber; Mackenzie Hurlston; Tammy Evans-Strickfaden; Tanmoy Bhattacharya; Elena E Giorgi; Joseph Mulenga; Etienne Karita; Bette T Korber; Susan Allen; Clyde E Hart; Cynthia A Derdeyn; Eric Hunter
Journal:  Proc Natl Acad Sci U S A       Date:  2011-11-07       Impact factor: 11.205

Review 4.  Antiretroviral therapy: a key component of a comprehensive HIV prevention strategy.

Authors:  Mark W Hull; Julio Montaner
Journal:  Curr HIV/AIDS Rep       Date:  2011-06       Impact factor: 5.071

5.  Challenges in initiating antiretroviral therapy in 2010.

Authors:  Cécile L Tremblay; Jean-Guy Baril; David Fletcher; Donald Kilby; Paul Macpherson; Stephen D Shafran; Mark W Tyndall
Journal:  Can J Infect Dis Med Microbiol       Date:  2010-08       Impact factor: 2.471

6.  Sexually transmitted infections and infectiousness beliefs among people living with HIV/AIDS: implications for HIV treatment as prevention.

Authors:  S C Kalichman; L Eaton; C Cherry
Journal:  HIV Med       Date:  2010-03-01       Impact factor: 3.180

Review 7.  Overcoming pharmacologic sanctuaries.

Authors:  Theodore J Cory; Timothy W Schacker; Mario Stevenson; Courtney V Fletcher
Journal:  Curr Opin HIV AIDS       Date:  2013-05       Impact factor: 4.283

8.  Short communication: human immunodeficiency virus rebound in blood and seminal plasma following discontinuation of antiretroviral therapy.

Authors:  Cecilia T Costiniuk; Colin Kovacs; Jean-Pierre Routy; Joel Singer; Sanjay Gurunathan; Rafick-Pierre Sekaly; Jonathan B Angel
Journal:  AIDS Res Hum Retroviruses       Date:  2012-09-25       Impact factor: 2.205

9.  Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women.

Authors:  Julie B Dumond; Melanie R Nicol; Racheal N Kendrick; Samira M Garonzik; Kristine B Patterson; Myron S Cohen; Alan Forrest; Angela D M Kashuba
Journal:  Clin Pharmacokinet       Date:  2012-12       Impact factor: 6.447

10.  HIV transmission in discordant couples in Africa in the context of antiretroviral therapy availability.

Authors:  Evonne Woodson; Alec Goldberg; Clive Michelo; Debby Basu; Sijia Tao; Raymond Schinazi; Yong Jiang; William Kilembe; Etienne Karita; Susan Allen; Eric Hunter
Journal:  AIDS       Date:  2018-07-31       Impact factor: 4.177

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.